NNovo Nordisk Read More Novo Nordisk’s Hemophilia Data Offers Rare Bright Spot as Revenue Guidance Darkens2026-04-30 Novo Nordisk’s hemophilia A drug Denecimig shows 99% fewer bleeds in Phase 3, bolstering FDA filing as GLP-1…